P2RX7 and glomerulonephritis: Indeed, P2X7 receptor ligands have been tested, with encouraging results, in preclinical models of inflammation (chronic pulmonary diseases, glomerulonephritis, rheumatoid arthritis, multiple sclerosis) [22].